Hims & Hers shares surge 50% after Novo Nordisk ends legal feud over compounded weight loss drugs

Novo dropped its patent-infringement suit against telehealth provider Hims & Hers after the parties agreed that Hims will sell Novo's branded medicines. The deal resolves litigation risk and creates a new commercial distribution channel for Novo's products via Hims, likely a modest positive for revenues and cost avoidance for both companies.

Analysis

Novo dropped its patent-infringement suit against telehealth provider Hims & Hers after the parties agreed that Hims will sell Novo's branded medicines. The deal resolves litigation risk and creates a new commercial distribution channel for Novo's products via Hims, likely a modest positive for revenues and cost avoidance for both companies.